UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 14, 2020
Aridis Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 001-38630 | | 47-2641188 |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (I. R. S. Employer
Identification No.) |
5941 Optical Ct.
San Jose, California 95138
(Address of principal executive offices, including ZIP code)
(408) 385-1742
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: | | Trading Symbol(s) | | Name of each exchange on which registered: |
Common Stock | | ARDS | | Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 1.01 Entry into a Material Definitive Agreement.
On October 14, 2020, Aridis Pharmaceuticals, Inc. (the “Company”) entered into a lease agreement (the “Lease Agreement”) with Boccardo Corporation (the “Landlord”) pursuant to which the Company leased approximately 15,129 square feet of office and laboratory space in Los Gatos, California which will serve as the Company’s headquarters. The lease represents additional space for the Company’s headquarters as compared to its prior lease. The lease is scheduled to commence on December 1, 2020 and has an approximate five year term (the “Initial Term”).
Rental payments by the Company commence on February 1, 2021. Base rent for the first year is approximately $492,000 (after giving effect to two months of rent abatement in the first year), increasing to approximately $668,000 million in the final year of the Initial Term. The Company is required to deliver a security deposit in the form of a letter of credit of $500,000 to the Landlord in connection with the Lease.
The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Lease Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The disclosure included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 20, 2020 | ARIDIS PHARMACEUTICALS, INC. |
| |
| /s/ Vu Truong |
| Vu Truong |
| Chief Executive Officer |
3
